Cramer 5-marker panel for ovarian cancer
The PLCO phase III specimens (test half) revealed marker panels produced only marginal improvement over CA 125 alone and, in some case, worse performance. Besides searching for new markers, some ways to improve detection might include: 1) Add epidemiologic variables, and 2) Add in prior markers values.
There are no datasets associated with this biomarker.
The following organs have data associated with this biomarker…
The PLCO accepted the phase II reports (SPORE/EDRN/PLCO Ovarian Validation Study) and sent identical sets to the assay sites. Each set included sera for cases most proximate to the diagnosis of ovarian cancer which (on average) was about 9 months prior. There were 951 controls matched by age and timing of specimen collection including 475 general population controls, 238 with false positive CA 125, and 238 with family history of breast or ovarian cancer. 90 quality control specimens were also included. Investigators tested their markers and marker panels blinded to the status of the cases. PLCO unblinded the data in stages to allow further algorithm development.
No associated resources found.